Articles On Imugene (ASX:IMU)

The S&P/ASX 200 Index (ASX: XJO) put on a rocky performance on Wednesday, eventually closing the session 0.02% higher at 7,237.2 points. The fall came as Reserve Bank of Australia (RBA) governor Philip Lowe addressed the National Pres...

Red 5 (RED) has logged its strongest month of production to date. In March, more than 17,000 ounces of gold was produced from the company’s King of the Hills gold mine in Western Australia. RED shares were trading above 16 cents as go...

This content is created by Smallcaps Authors. [Author : Danica Cullinane] Clinical stage immune-oncology company Imugene (ASX: IMU) has announced it has started dosing a third cohort of patients in the intravenous (IV) and intratumoral (I...

Imugene (IMU) doses its first patients in the intravenous and intratumoral arms in cohort three of the monotherapy dose escalation trial The company’s phase one MAST study is evaluating the safety of cancer-killing virus CF33-hNIS (VAXI...

Highlights Imugene has dosed first patients in the intravenous and intratumoral arms in cohort 3 of the monotherapy dose escalation trial of its Phase 1 MAST study. A maximum of 100 patients will be recruited across 10 trial sites in A...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.78% in Friday’s session to close at 7,177.8 points. That leaves it 3.2% higher week-on-week. And many of its top performers were mining stocks. The S&P/ASX 200...

The S&P/ASX 200 Index (ASX: XJO) slipped lower on Friday, falling 0.19% to close at 6,955.2 points. That leaves the index 0.57% lower week on week. It came on the back of rate hikes in the United Kingdom, Switzerland, and Norway overni...

The S&P/ASX 200 Index (ASX: XJO) recovered some of its Monday losses today, closing Tuesday’s session 0.82% higher at 6,955.4 points. The Aussie bourse’s day in the green followed a strong night’s trade over on Wall Street. The...

ShareCafeBig gains from Tech push ASX 0.86% higher by Peter Milios   The Australian stock market experienced a 0.89 per cent increase, reaching 7068.9 points, mainly due to growth in the technology industry. Link Administration (ASX:LNK) ha...

The share market surged to a two-week high after the Reserve Bank softened its interest rates guidance after raising the cash rate target for a record tenth straight time and suggesting inflation has peaked. Stocks popped and the dollar...

Aussie shares hovered near a two-week high in cautious trade ahead of this afternoon’s RBA interest rate announcement. Declines in mining and tech stocks helped ease the S&P/ASX 200 down two points or 0.02 per cent. Gains in supermar...

This content is created by Smallcaps Authors. [Author : Danica Cullinane] Immuno-oncology company Imugene (ASX: IMU) has collared a patent in the United States for its PD1-Vaxx immunotherapy for lung cancer, while clinical trials of its n...

Cancer cure researcher Imugene has announced that the first patients for its Phase 1 vaxinia combination trial have been dosed, kick-starting the all-important process of determining compatibility of vaxinia with pembrolizumab. The post Imu...

Imugene (IMU) doses the first patients in a combination study to test its cancer-killing virus, VAXINIA, along with antibody cancer drug Pembrolizumab The patients were dosed intravenously (IV) and intratumorally (IT) as part of IMU’s Ph...

Highlights Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab. The study is focused on measu...

The S&P/ASX 200 Index (ASX: XJO) ended the week in the red, falling 0.86% on Friday to close at 7,346.8 points. That leaves it down 1.17% week-on-week. Today’s tumble followed an equally disappointing overnight session on Wall Street...

The Treasury Wine Estates Ltd (ASX: TWE) share price is on the slide on Wednesday morning. At the time of writing, the wine giant’s shares are down 7% to $13.33. This follows the release of the company’s half year results. Treasury Win...

The Appen Ltd (ASX: APX) share price has been in a bit of a sorry state for a while now. Appen shares have dived today, for one. The All Ords tech share is currently down by a nasty 3.91% at $2.70 a share so far this Tuesday. But Appen’s w...

ShareCafeEnergy’s efforts are not enough to lift the ASX by Peter Milios   The ASX 200 index fell by 0.2 per cent to 7417.8 today, due to a decrease in the consumer discretionary sector. However, Energy closed 1.78 per cent higher as Russia...

ASX artificial intelligence (AI) stocks haven’t had a great run over the past 12 months. To say the least. Atop some company-specific issues, AI companies came under selling pressure as global interest rates shot up from historic lows to...

The Appen Ltd (ASX: APX) share price is taking a tumble, down 9.9% in Monday morning trade. The artificial intelligence (AI) data services company saw its shares rocket last week, gaining 28% over the past four trading days. With no price-...

The Endeavour Group Ltd (ASX: EDV) share price is charging ahead after the company dropped its earnings for the first half of financial year 2023 this morning. Shares in the drinks retailer and hotel operator are trading 4.69% higher at $7...

There are plenty of blue chip ASX 200 shares to choose from on the Australian share market. But three of the best, according to Morgans, are listed below. Here’s why the broker thinks highly of these blue chips: Treasury Wine Estates Lt...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a disappointing note. The benchmark index fell 0.75% to 7,433.7 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 20...

ShareCafeASX closes 0.8% lower as UBS lift their cash rate peak forecast by Peter Milios   UBS Chief Economist George Tharenou has revised his peak cash rate forecast to 3.85 per cent in mid-2023, up from a previous forecast of 3.35 per cen...

The S&P/ASX 200 Index (ASX: XJO) ended the week just the way it started it – in the red. The index closed Friday’s session 0.76% lower at 7,433.7 points, marking a 1.65% week-on-week fall. It came as the Reserve Bank of Australia i...

Reporting from Sydney this morning, clinical-stage cancer immunotherapy developer Imugene [ASX:IMU] made the upbeat announcement that it now has a patent to treat patients in the US. A Notice of Allowance from the US Patent and Trademark Of...

The share market’s sparkling start to the year lost some of its fizz as the threat of higher interest rates dragged the Australian benchmark to its first losing week of 2023. The S&P/ASX 200 slid 56.6 points or 0.76 per cent this aft...

Shares fall to a three-week low amid RBA's 'hawkish' update. CBA says rate cut needed by end of year to avoid 'hard landing'. Allkem CFO dies of illness. Imugene soars on patent approval.

The share market slumped to a two-and-a-half week low as financial markets continued to adjust their expectations for the top of this interest rate cycle. The S&P/ASX 200 declined 51 points or 0.68 per cent by mid-session. The fall k...

ShareCafeASX down at noon despite RBA comments that inflation has likely peaked by Peter Milios   The Reserve Bank of Australia has revised its inflation forecasts, stating that the rapidly rising prices in the country have probably peaked....

ShareCafeStocks of the Hour: CZL, RGL, ALA                    Consolidated Zinc (ASX:CZL) has entered into a binding agreement with Impact Silver Corp. to sell its Plomosas Project in Mexico. In response, Brad Marwood, Executive Chair...

Highlights Imugene Limited has secured a Notice of Allowance relating a US patent application for its B-cell activating immunotherapy PD1-Vaxx. PD1-Vaxx is undergoing clinical development for non-small cell lung cancer. The patent tit...

The share price of S&P/ASX 200 Index (ASX: XJO) biopharmaceutical developer Imugene Limited (ASX: IMU) is soaring on Friday after the company announced a new United States patent. The patent relates to its B-cell activating immunothera...

Imugene (IMU) receives a Notice of Allowance from the US Patent and Trademark Office for its PD1-Vaxx technology The patent protects the composition of matter and method of treatment for PD1-Vaxx in cancer until 2038 PD1-Vaxx is a B-c...

The ASX will open lower on Friday after a Wall Street slump overnight Disney and Yahoo to lay off thousands of employees RBA expected to revise inflations forecasts today   The ASX is poised to open lower this morning as US stocks faded i...

The S&P/ASX 200 Index (ASX: XJO) posted its first gain of the week on Wednesday, lifting 0.35% to close at 7,530.1 points. It followed a strong session over on Wall Street. The Dow Jones Industrial Average Index (DJX: .DJI) rose 0.8% o...

ShareCafeASX closes 0.13% higher as Bitcoin spikes and China lifts coal ban by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.13 per cent higher at 7,511.6. Bitcoin hit its highest point since August due to investor interpret...

ShareCafeASX up 0.58% at noon after Fed comments of decreasing inflation by Peter Milios   The ASX has increased 0.58 per cent at noon, as Wall Street gained following Federal Reserve Chairman Jerome Powell’s comments that financial conditi...

Imugene (IMU) advances its phase one metastatic advanced solid tumours study The phase one trial of IMU’s VAXINIA cancer-killing virus has cleared the second cohort in both the intravenous (IV) and intratumoral (IT) arms of the monothera...

Highlights Imugene Limited’s Phase 1 MAST study has cleared cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial. The company will now commence cohort 1 of the combination study (with Pembrolizumab)...

02 Feb 2023 - A snapshot of the stocks on the move featuring Splitit (ASX:SPT), European Metals Holdings (ASX:EMH) and Alchemy Resources (ASX:ALY).

ShareCafeStocks of the Hour: SPT, EMH, IMU, ALY                    Buy Now Pay Later platform, Splitit (ASX:SPT), has signed a partnership agreement with Ingenico, to create the first one-touch instalment solution embedded into physic...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Highlights A new 100-day high for ASX 200 was noted at market close on 1 February 2023. The ASX 200 was up, gaining 0.33% to 7,501.70. Over the past five days, ASX 200 has gained 0.45%. Top performers of the day included Flight Centr...

The S&P/ASX 200 Index (ASX: XJO) shot to a nine-month high of 7,537.7 points today. However, by the time the market closed it was sitting at 7,501.7 points – marking a 0.33% gain. And leading the way was the S&P/ASX 200 Real Esta...

The share market cruised to a fresh nine-month high after Wall Street rallied into tonight’s interest rate decision. The S&P/ASX 200 put on as much as 61 points in early action before paring its rise to 25 points or 0.33 per cent. To...

The share market recovery of 2023 got back on track as a first rise in three sessions lifted the S&P/ASX 200 to a fresh nine-month high. The Australian benchmark rose to within 1.3 per cent of its 2021 record before trimming its clim...

ShareCafeAus shares close 0.07% lower but rise 6.2% in January by Peter Milios   Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks...

ShareCafeHigh cost of living causes a fall in retail sales: ASX up 0.22% at noon by Peter Milios   Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the...